海西新药：商业化阶段制药企业，通过港交所聆讯

Group 1 - The core viewpoint of the article is that Fujian Haixi New Drug Creation Co., Ltd. is preparing for an upcoming IPO in Hong Kong, with the aim of raising funds for various developmental and operational purposes [1][2] Group 2 - Haixi New Drug is a commercial-stage pharmaceutical company that integrates research and development, production, and sales capabilities, with a diverse pipeline of innovative drugs [2] - The company has a product portfolio focused on therapeutic areas such as digestive, cardiovascular, endocrine, neurological, and inflammatory diseases, with its commercialized products primarily being generic drugs [2] - Haixi New Drug has received approval from the National Medical Products Administration for 15 generic drugs and has established a pipeline of four innovative drugs, along with a global patent portfolio comprising 36 patents [2]